A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

• Status: Completed
• Trial end date: 2020-08-13

Summary

MORAb-003-011 is a global, multicenter, double-blind, randomized placebo-controlled study to assess the safety and efficacy of farletuzumab in combination with standard chemotherapy in subjects with low cancer antigen 125 (CA125) platinum-sensitive ovarian cancer in first relapse.

• Phase: Phase 2

Details

• Lead Sponsor: Eisai Inc.; Morphotek
• Collaborator: Eisai Co., Ltd.
• Treatments: Carboplatin; Doxorubicin; Farletuzumab; Liposomal doxorubicin; Paclitaxel